Interim analysis of ELEANOR (n=200): a multi-national, prospective, non-interventional study (NIS) among patients with HER2+and HR+ early breast cancer (eBC) treated with extended adjuvant neratinib

被引：0
|
作者：
Bartsch, R. [1 ]
Harbeck, N. [2 ,3 ]
Wrobel, D. [4 ]
Zaiss, M. [5 ]
Terhaag, J. [6 ]
Guth, D. [7 ]
Distelrath, A. [8 ]
Wuerstlein, R. [2 ,3 ]
Zahn, M. -O. [9 ]
Lueftner, D. [10 ,11 ]
Schwitter, M. [12 ]
Balic, M. [13 ]
Jackisch, C. [14 ]
Mueller, V. [15 ]
Rinnerthaler, G. [16 ]
Schmidt, M. [17 ]
Zaman, K. [18 ]
Schinkoethe, T. [19 ]
Gorray, M. [20 ]
Breitenstein, U. [21 ]
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] LMU Univ Hosp, Dept OB GYN, Breast Ctr, Munich, Germany
[3] LMU Univ Hosp, CCC Munich, Munich, Germany
[4] Sozialstiftung Bamberg Klinikum Bruderwald, Bamberg, Germany
[5] Oncol Practice, Freiburg, Germany
[6] Rottal Inn Clin, Eggenfelden, Germany
[7] Gyneco Oncol Practice Dr Guth, Plauen, Germany
[8] Praxisgemeinschaft Onkol & Urol, Wilhelmshaven, Germany
[9] MVZ Onkol Kooperat Harz, Goslar, Germany
[10] Immanuel Hosp Mark Schweiz, Brandenburg, Germany
[11] Med Univ Brandenburg Theodor Fontane, Brandenburg, Germany
[12] Kantonsspital Graubunden, Chur, Switzerland
[13] Med Univ Graz, Dept Internal Med, Div Oncol, Graz, Austria
[14] Sana Klinikum Offenbach, Dept Gynecol & Obstet, Offenbach, Germany
[15] Univ Hosp Hamburg Eppendorf, Dept Gynecol & Obstet, Hamburg, Germany
[16] Paracelsus Med Univ Salzburg, Dept Internal Med 3, Salzburg, Austria
[17] Univ Hosp Mainz, Dept Gynecol, Mainz, Germany
[18] Lausanne Univ Hosp CHUV, Breast Ctr, Lausanne, Switzerland
[19] CANKADO Serv GmbH, Kirchheim, Germany
[20] Pierre Fabre Pharma GmbH, Freiburg, Germany
[21] Brust Zentrum Zurich, Div Oncol, Zurich, Switzerland
来源：
BREAST | 2023年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P014
引用
下载
收藏
页码：S20 / S21
页数：2
相关论文
共 42 条
  • [31] Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2-advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT
    Steger, Guenther G.
    Egle, Daniel
    Bartsch, Rupert
    Pfeiler, Georg
    Petru, Edgar
    Greil, Richard
    Helfgott, Ruth
    Marth, Christian
    Oehler, Leopold
    Hubalek, Michael
    Lang, Alois
    Tinchon, Christoph
    Haslbauer, Ferdinand
    Redl, Andreas
    Hock, Karin
    Hennebelle, Mathias
    Mraz, Bernhard
    Gnant, Michael
    BREAST, 2020, 50 : 64 - 70
  • [32] Validation Study of Algorithms to Identify Cancer Metastasis/Recurrence in Patients With High-Risk HR+/HER2-Early Breast Cancer (EBC) Using Japan Nationwide Hospital-Based Databases Owned By National Hospital Organization
    Inoue, N.
    Tani, T.
    Kanazawa, N.
    Tokunaga, E.
    Aogi, K.
    Horiguchi, H.
    Cai, Z.
    Osage, S.
    Kawaguchi, T.
    Tanizawa, Y.
    VALUE IN HEALTH, 2022, 25 (12) : S497 - S497
  • [33] Adjuvant chemotherapy for pT1-3N0-1 breast cancer patients with HR+, HER2-subtype: a propensity-score matched study with competing risk analysis
    Dong, Hong
    Su, Xinyu
    Li, Xun
    Fu, Peng
    Tan, Lun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 12637 - 12646
  • [34] Adjuvant chemotherapy for pT1-3N0-1 breast cancer patients with HR+, HER2− subtype: a propensity-score matched study with competing risk analysis
    Hong Dong
    Xinyu Su
    Xun Li
    Peng Fu
    Lun Tan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 12637 - 12646
  • [35] Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Thill, Marc
    Wimberger, Pauline
    Grafe, Andrea
    Klare, Peter
    Luedtke-Heckenkamp, Kerstin
    Reichert, Dietmar
    Zaiss, Matthias
    Ziegler-Loehr, Katja
    Eckl, Tanja
    Schneeweiss, Andreas
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 196 (02) : 311 - 321
  • [36] Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Marc Thill
    Pauline Wimberger
    Andrea Grafe
    Peter Klare
    Kerstin Luedtke-Heckenkamp
    Dietmar Reichert
    Matthias Zaiss
    Katja Ziegler-Löhr
    Tanja Eckl
    Andreas Schneeweiss
    Breast Cancer Research and Treatment, 2022, 196 : 311 - 321
  • [37] POTENTIAL LONG-TERM BENEFITS OF EXTENDED ADJUVANT NERATINIB IN PATIENTS WITH HIGH-RISK HORMONE RECEPTOR POSITIVE (HR+) HER2+EARLY-STAGE BREAST CANCER (ESBC) FOLLOWING USE OF T-DM1 OR PERTUZUMAB: A POPULATION EFFECTIVENESS MODEL
    Veenstra, D.
    Oestreicher, N.
    Dolan, C. M.
    Fisher, K. A.
    Pandey, R.
    Elsea, D.
    Brufsky, A.
    VALUE IN HEALTH, 2023, 26 (06) : S153 - S153
  • [38] Dual HER2-blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T. Results from a German non-interventional study (NIS) HELENA (NCT01777958)
    Thill, Marc
    Auth, Lead
    Grafe, Andrea
    Klare, Peter
    Luedtke-Heckenkamp, Kerstin
    Reichert, Dietmar
    Wimberger, Pauline
    Zaiss, Matthias
    Ziegler-Loehr, Katja
    Eckl, Tanja
    Schneeweiss, Andreas
    CANCER RESEARCH, 2022, 82 (04)
  • [39] Real-world evidence: interim analysis of efficacy in 628 patients with stage IIIB/IV non-small cell lung cancer (NSCLC) treated with Nivolumab after prior chemotherapy in a national, prospective, non-Interventional study (ENLARGE-Lung)
    Sebastian, M.
    Groeschel, A.
    Guetz, S.
    Schulz, H.
    Mueller-Huesmann, H.
    Schulte, C.
    Wuensch, V.
    Schumann, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 133 - 133
  • [40] Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC): A US database analysis.
    Graff, Stephanie L.
    Tolaney, Sara M.
    Hart, Lowell L.
    Razavi, Pedram
    Fasching, Peter A.
    Janni, Wolfgang
    Schwartzberg, Lee S.
    Lanoue, Brad
    Salas, Tonatiuh Romero
    Khakwani, Aamir
    McDermott, Courtney
    Pathak, Purnima
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345